Cargando…

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

Evidence of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking. To determine whether TXA safely reduces bleeding incidence in patients undergoing treatment for hematologic malignancies, a randomized, double-blind clinical trial was conducted from June 2016...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gernsheimer, Terry B., Brown, Siobhan P., Triulzi, Darrell J., Key, Nigel S., El Kassar, Nahed, Herren, Heather, Poston, Jacqueline N., Boyiadzis, Michael, Reeves, Brandi N., Selukar, Subodh, Pagano, Monica B., Emerson, Scott, May, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479029/ https://www.ncbi.nlm.nih.gov/pubmed/35667085 http://dx.doi.org/10.1182/blood.2022016308

Ejemplares similares

Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia
por: Ilich, Anton, et al.
Publicado: (2022)

Hematologic complications with age in Shwachman-Diamond syndrome
por: Furutani, Elissa, et al.
Publicado: (2022)

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors
por: Sahinoz, Melis, et al.
Publicado: (2022)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia
por: Engelmann, Robby, et al.
Publicado: (2023)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
por: Davids, Matthew S., et al.
Publicado: (2021)

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
por: Allen, Pamela B., et al.
Publicado: (2022)

Circulating SARS-CoV-2(+) megakaryocytes are associated with severe viral infection in COVID-19
por: Fortmann, Seth D., et al.
Publicado: (2023)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
por: Perry, C., et al.
Publicado: (2021)

Anti-glycoprotein antibodies and sequestration pattern of indium-labeled platelets in immune thrombocytopenia
por: Amini, Sufia N., et al.
Publicado: (2022)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
por: Steffin, David H. M., et al.
Publicado: (2022)

Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial
por: Ausen, K., et al.
Publicado: (2019)

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
por: Herrera, Alex F., et al.
Publicado: (2022)

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
por: Ruan, Jia, et al.
Publicado: (2023)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022)

Randomized clinical trial of topical tranexamic acid after reduction mammoplasty
por: Ausen, K, et al.
Publicado: (2015)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score–weighted study
por: Ingason, Arnar B., et al.
Publicado: (2022)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials
por: Valtis, Yannis K., et al.
Publicado: (2021)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
por: Shimony, Shai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7t55e90ta65f5t97sib8sevc1d